<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470015</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000542631</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0575</secondary_id>
    <secondary_id>06-002650</secondary_id>
    <secondary_id>NCI-2009-1306</secondary_id>
    <nct_id>NCT00470015</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma</brief_title>
  <official_title>Melanoma Peptide Vaccines (MART1 Analog, gp100 and Survivin) With GM-CSF and Low-Dose IL-2 as Immune Adjuvants, A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may help the body build an effective immune response&#xD;
      to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of&#xD;
      immune cells found in bone marrow or peripheral blood. Aldesleukin may stimulate the white&#xD;
      blood cells to kill tumor cells. Giving vaccine and different doses of GM-CSF mixed in&#xD;
      incomplete Freund's adjuvant, with or without aldesleukin, may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and how well giving vaccine therapy&#xD;
      together with GM-CSF, with or without low-dose aldesleukin, works in treating patients with&#xD;
      stage II, stage III, or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and toxicity profile of peptide vaccine comprising MART-1 antigen,&#xD;
           gp100 antigen, and survivin antigen in combination with sargramostim (GM-CSF) emulsified&#xD;
           in incomplete Freund's adjuvant (IFA) with or without low-dose aldesleukin in patients&#xD;
           with stage II-IV melanoma.&#xD;
&#xD;
        -  Determine the immunologic effects of two different doses of GM-CSF coemulsified with&#xD;
           melanoma peptides in IFA in these patients.&#xD;
&#xD;
        -  Determine the immunological effects of low-dose aldesleukin therapy administered after&#xD;
           peptide immunization in these patients.&#xD;
&#xD;
        -  Collect preliminary data on the impact of the vaccine on clinical outcomes in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study. Patients are stratified according to disease stage (II vs III&#xD;
      or IV). Patients are sequentially enrolled into 1 of 4 different dose schedules.&#xD;
&#xD;
        -  Dose schedule 1: Patients receive gp100 antigen, MART-1 antigen, survivin antigen, and&#xD;
           sargramostim (GM-CSF) emulsified in incomplete Freund's adjuvant (peptide vaccine)&#xD;
           subcutaneously (SC) on day 1. Treatment repeats every 21 days for 4 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Dose schedule 2: Patients receive peptide vaccine as in group 1. Patients also receive&#xD;
           low-dose aldesleukin SC twice daily on days 7-20. Treatment repeats every 21 days for 4&#xD;
           courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Dose schedule 3: Patients receive peptide vaccine as in group 1 except with a higher&#xD;
           dose of GM-CSF. Treatment repeats every 21 days for 4 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Dose schedule 4: Patients receive peptide vaccine as in group 1 except with a higher&#xD;
           dose of GM-CSF. Patients also receive low-dose aldesleukin SC twice daily on days 7-20.&#xD;
           Treatment repeats every 21 days for 4 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 5 patients receive treatment at subsequent dose schedule until the maximum&#xD;
      tolerated dose schedule (MTDS) is determined. The MTDS is defined as the dose schedule&#xD;
      preceding that at which 2 of 5 patients experience dose-limiting toxicity within the first&#xD;
      course.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2007</start_date>
  <completion_date type="Actual">January 2, 2013</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent changes in peptide vaccine-specific immune responses (tetramer frequencies) from pretreatment levels</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and severity of hematologic and nonhematologic toxicities observed at each dose level</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delayed-type hypersensitivity positivity</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum percent change in CD4, CD8, CD14, CD19, and C20 levels from preimmunization levels</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>MART1 Analog, gp100 and Survivin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
    <description>1000 mcg; Day 1 of a 21 day cycle x 4</description>
    <arm_group_label>MART1 Analog, gp100 and Survivin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>0.5x10^6/m^2</description>
    <arm_group_label>MART1 Analog, gp100 and Survivin</arm_group_label>
    <other_name>Interleukin-2, Proleukin®, aldesleukin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
    <description>1000 mcg; Day 1 of a 21 day cycle x 4</description>
    <arm_group_label>MART1 Analog, gp100 and Survivin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>300mcg</description>
    <arm_group_label>MART1 Analog, gp100 and Survivin</arm_group_label>
    <other_name>Leukine-Liquid, sargramostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1a peptide</intervention_name>
    <description>1000 mcg; Day 1 of a 21 day cycle x 4</description>
    <arm_group_label>MART1 Analog, gp100 and Survivin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed melanoma&#xD;
&#xD;
               -  Stage II-IV disease&#xD;
&#xD;
          -  Completely resected disease&#xD;
&#xD;
          -  No known standard therapy that is potentially curative or proven capable of extending&#xD;
             life expectancy exists&#xD;
&#xD;
          -  HLA-A2 positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm³&#xD;
&#xD;
          -  AST ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled or current infection&#xD;
&#xD;
          -  No known allergy to vaccine or immunoadjuvant components&#xD;
&#xD;
          -  No known immune deficiency&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No chemotherapy within the past 4 weeks and recovered&#xD;
&#xD;
          -  No biologic therapy within the past 4 weeks&#xD;
&#xD;
          -  No radiation therapy within the past 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svetomir Markovic, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>February 15, 2019</last_update_submitted>
  <last_update_submitted_qc>February 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

